- Email: [email protected]
Availability of canthaxanthin in the United States
Volume 12 Number 1, Part l January, 1985
2. Chernovsky ME, Derbes VJ, Burks JW: Lichen sclerosus et atrophicus in children. Arch Dermatol 75:647-652, 1957. 3. Clark JA, Muller SA: Lichen sclerosus et atrophicus in children. Arch Dermatol 95:476-482, 1967. 4. Rowell NR: Lichen sclerosus, in Rook A, Wilkinson DS, Ebling FJG, editors: Textbook of dermatology. Oxford, 1979, Blackwell Scientific Publications, pp. 1231-1235. 5. Purres J, Kmll EA: Lichen sclerosus et atrophicus involving the palms. Arch Dermatol 104:68-69, 1971. 6. Miller RF: Lichen sclerosus et atrophicus with oral involvement. Arch Dermatol 76:43-55, 1957. 7. Clark JA, Muller SA: Lichen sclerosus et atrophicus in children. Arch Dermatol 95:476-482, 1967, 8. Anderton RL, Abelc DC: Lichen sclemsus et atrophicus in a vaccination site. Arch Dermatol 112:1787, 1976. (Letter to Editor.) 9. Wallace HJ: Lichen sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc 57:9-30, 197 l. 10. Barker LP, Gross P: Lichen sclemsus et atrophieus of the female genitalia. Arch Dcrmatol 85:362-373, 1962. I I. Goolamali SK, Barnes EW, lrvine WJ, ct al: Organspecific antibodies in patients with lichen sclerosus. Br Med J 4:78-79, 1974. 12. Chorzelski T, Jablonska S, Blaszczyk M: Immunopathological investigations in the Senear Usher syndrome (coexistence of pemphigus and lupus erythematosus). Br J Dermatol 80:211-217, 1968. 13. Bean SF, Lynch FW: Scncar-Usher syndrome (pemphigus erythematosus). Arch Dermatol 101:642-645, 1970. 14. Siakia NK, Macconnell LES: Senear-Usher syndrome and internal malignancy. Br J Dermatol 87:1-5, 1970. 15. Jordon RE, Muller SA: Bullous pemphigoid associated with systemic lupus erythematosus. Arch Dermatol 99:17-25, 1969. 16. Mooncada R: Dermatitis herpetiformis in association with systemic lupus erythematosus. Arch Dcrmatol 109:723-725, 1974. 17, Aronson AJ, Keyoumars S, Aronson IK: Systemic lupus erythematosus and dermatitis herpetiformis. Arch Dermatol 115:68-70, 1979. 18. Chorzelski T, Jablonska S: Coexistence of lupus erythematosus and scleroderma in light of immunopathological investigations. Acta Derm Venereol (Stockh) 50:81-85, 1970.
Correspondence
129
coloring under the name Food Orange 8, although the amounts likely to be ingested in foods would be small.
Fred Levit, M.D. 707 Fairbanks Court, Chicago, IL 60611
Reply To the Editor: While canthaxanthin in the small amounts added to foods as a colorant has indeed been approved by the Food and Drug Administration (FDA) for some time, the ingestion of large amounts as a photoprotectant drug, analogous to preparations marketed in Europe and Canada (and perhaps elsewhere), has not been approved in this country. Over-the-counter preparations have indeed recently begun to appear in the United States. In addition to the compound mentioned by Dr. Levit, I have seen another advertisement for canthaxanthin from a health food store in Texas under the name of "Riviera." Both of these products are touted as "sunless tanning" agents because of the color imparted to the skin when large amounts of them are ingested. Communication with the major pharmaceutical house that manufactures this carotenoid indicates that they do not now have, and have no current intent to apply for, FDA approval for marketing this agent either as a prescription-limited or an over-the-counter medication. They were not aware of its availability as noted in the advertisements.
Maureen B. Poh-Fitzpatrick, M,D. Department of Dermatology College of Physicians and Surgeons of Columbia University New York, NY 10032
Lynch s y n d r o m e I I and Lynch syndrome I Availabiltiy of canthaxanthin in the United States To the Editor: In their recent article (J AM ACAD DERMATOL 11:11 1-113, 1984) Poh-Fitzpatrick and Barbera mention that canthaxanthin, the carotenoid responsible for crystalline retinopathy in Canadian patients, is not available in the United States. This material has recently begun to be advertised and sold here as a nonprescription tanning agent. One preparation has the name Solarin-950 and is available by mail. In addition, canthaxanthin is listed for use as a food
To the Editor: Banse-Kupin, Morales and Barlow (J AM ACAD DgrMATOL 10:803-817, 1984) repotted two family pedigrees of Torre's syndrome (Cancer Family syndrome, CFS; Muir-Torre's syndrome, MT). The family pedigree of Patient 1 appeared to be CFS (Lynch syndrome II); however, the data on the family pedigree of Patient 2 appeared to be Lynch syndrome 1. ~ The proband in the second patient had two sebaceous adenomas. Since no other members had their integument described and cancers of several organ systems were not present, it was premature to assign the proband in the second family the designation Torre's syndrome.
2. Chernovsky ME, Derbes VJ, Burks JW: Lichen sclerosus et atrophicus in children. Arch Dermatol 75:647-652, 1957. 3. Clark JA, Muller SA: Lichen sclerosus et atrophicus in children. Arch Dermatol 95:476-482, 1967. 4. Rowell NR: Lichen sclerosus, in Rook A, Wilkinson DS, Ebling FJG, editors: Textbook of dermatology. Oxford, 1979, Blackwell Scientific Publications, pp. 1231-1235. 5. Purres J, Kmll EA: Lichen sclerosus et atrophicus involving the palms. Arch Dermatol 104:68-69, 1971. 6. Miller RF: Lichen sclerosus et atrophicus with oral involvement. Arch Dermatol 76:43-55, 1957. 7. Clark JA, Muller SA: Lichen sclerosus et atrophicus in children. Arch Dermatol 95:476-482, 1967, 8. Anderton RL, Abelc DC: Lichen sclemsus et atrophicus in a vaccination site. Arch Dermatol 112:1787, 1976. (Letter to Editor.) 9. Wallace HJ: Lichen sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc 57:9-30, 197 l. 10. Barker LP, Gross P: Lichen sclemsus et atrophieus of the female genitalia. Arch Dcrmatol 85:362-373, 1962. I I. Goolamali SK, Barnes EW, lrvine WJ, ct al: Organspecific antibodies in patients with lichen sclerosus. Br Med J 4:78-79, 1974. 12. Chorzelski T, Jablonska S, Blaszczyk M: Immunopathological investigations in the Senear Usher syndrome (coexistence of pemphigus and lupus erythematosus). Br J Dermatol 80:211-217, 1968. 13. Bean SF, Lynch FW: Scncar-Usher syndrome (pemphigus erythematosus). Arch Dermatol 101:642-645, 1970. 14. Siakia NK, Macconnell LES: Senear-Usher syndrome and internal malignancy. Br J Dermatol 87:1-5, 1970. 15. Jordon RE, Muller SA: Bullous pemphigoid associated with systemic lupus erythematosus. Arch Dermatol 99:17-25, 1969. 16. Mooncada R: Dermatitis herpetiformis in association with systemic lupus erythematosus. Arch Dcrmatol 109:723-725, 1974. 17, Aronson AJ, Keyoumars S, Aronson IK: Systemic lupus erythematosus and dermatitis herpetiformis. Arch Dermatol 115:68-70, 1979. 18. Chorzelski T, Jablonska S: Coexistence of lupus erythematosus and scleroderma in light of immunopathological investigations. Acta Derm Venereol (Stockh) 50:81-85, 1970.
Correspondence
129
coloring under the name Food Orange 8, although the amounts likely to be ingested in foods would be small.
Fred Levit, M.D. 707 Fairbanks Court, Chicago, IL 60611
Reply To the Editor: While canthaxanthin in the small amounts added to foods as a colorant has indeed been approved by the Food and Drug Administration (FDA) for some time, the ingestion of large amounts as a photoprotectant drug, analogous to preparations marketed in Europe and Canada (and perhaps elsewhere), has not been approved in this country. Over-the-counter preparations have indeed recently begun to appear in the United States. In addition to the compound mentioned by Dr. Levit, I have seen another advertisement for canthaxanthin from a health food store in Texas under the name of "Riviera." Both of these products are touted as "sunless tanning" agents because of the color imparted to the skin when large amounts of them are ingested. Communication with the major pharmaceutical house that manufactures this carotenoid indicates that they do not now have, and have no current intent to apply for, FDA approval for marketing this agent either as a prescription-limited or an over-the-counter medication. They were not aware of its availability as noted in the advertisements.
Maureen B. Poh-Fitzpatrick, M,D. Department of Dermatology College of Physicians and Surgeons of Columbia University New York, NY 10032
Lynch s y n d r o m e I I and Lynch syndrome I Availabiltiy of canthaxanthin in the United States To the Editor: In their recent article (J AM ACAD DERMATOL 11:11 1-113, 1984) Poh-Fitzpatrick and Barbera mention that canthaxanthin, the carotenoid responsible for crystalline retinopathy in Canadian patients, is not available in the United States. This material has recently begun to be advertised and sold here as a nonprescription tanning agent. One preparation has the name Solarin-950 and is available by mail. In addition, canthaxanthin is listed for use as a food
To the Editor: Banse-Kupin, Morales and Barlow (J AM ACAD DgrMATOL 10:803-817, 1984) repotted two family pedigrees of Torre's syndrome (Cancer Family syndrome, CFS; Muir-Torre's syndrome, MT). The family pedigree of Patient 1 appeared to be CFS (Lynch syndrome II); however, the data on the family pedigree of Patient 2 appeared to be Lynch syndrome 1. ~ The proband in the second patient had two sebaceous adenomas. Since no other members had their integument described and cancers of several organ systems were not present, it was premature to assign the proband in the second family the designation Torre's syndrome.